 | • レポートコード：MRC2Q12-18848 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、抗血管内皮増殖因子治療薬の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に抗血管内皮増殖因子治療薬のグローバル市場のxxx％を占める「アフリベルセプト（アイリーア）」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「黄斑浮腫」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 抗血管内皮増殖因子治療薬の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの抗血管内皮増殖因子治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 抗血管内皮増殖因子治療薬のグローバル主要プレイヤーには、Regeneron Pharmaceuticals、Bayer、Novartis、Roche、Biogen、Pfizer、Coherus BioSciences、Amgen、Bausch Health Companies、Viatrisなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 抗血管内皮増殖因子治療薬市場は、種類と用途によって区分されます。世界の抗血管内皮増殖因子治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 アフリベルセプト（アイリーア）、ラニビズマブ（ルセンティス）、ブロルシズマブ（ベオヴ）、その他 【用途別セグメント】 黄斑浮腫、糖尿病網膜症、網膜静脈閉塞症、加齢黄斑変性症、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 抗血管内皮増殖因子治療薬製品概要 - 種類別市場（アフリベルセプト（アイリーア）、ラニビズマブ（ルセンティス）、ブロルシズマブ（ベオヴ）、その他） - 用途別市場（黄斑浮腫、糖尿病網膜症、網膜静脈閉塞症、加齢黄斑変性症、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の抗血管内皮増殖因子治療薬販売量予測2017-2028 - 世界の抗血管内皮増殖因子治療薬売上予測2017-2028 - 抗血管内皮増殖因子治療薬の地域別販売量 - 抗血管内皮増殖因子治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別抗血管内皮増殖因子治療薬販売量 - 主要メーカー別抗血管内皮増殖因子治療薬売上 - 主要メーカー別抗血管内皮増殖因子治療薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（アフリベルセプト（アイリーア）、ラニビズマブ（ルセンティス）、ブロルシズマブ（ベオヴ）、その他） - 抗血管内皮増殖因子治療薬の種類別販売量 - 抗血管内皮増殖因子治療薬の種類別売上 - 抗血管内皮増殖因子治療薬の種類別価格 ・用途別市場規模（黄斑浮腫、糖尿病網膜症、網膜静脈閉塞症、加齢黄斑変性症、その他） - 抗血管内皮増殖因子治療薬の用途別販売量 - 抗血管内皮増殖因子治療薬の用途別売上 - 抗血管内皮増殖因子治療薬の用途別価格 ・北米市場 - 北米の抗血管内皮増殖因子治療薬市場規模（種類別、用途別） - 主要国別の抗血管内皮増殖因子治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの抗血管内皮増殖因子治療薬市場規模（種類別、用途別） - 主要国別の抗血管内皮増殖因子治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の抗血管内皮増殖因子治療薬市場規模（種類別、用途別） - 主要国別の抗血管内皮増殖因子治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の抗血管内皮増殖因子治療薬市場規模（種類別、用途別） - 主要国別の抗血管内皮増殖因子治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの抗血管内皮増殖因子治療薬市場規模（種類別、用途別） - 主要国別の抗血管内皮増殖因子治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Regeneron Pharmaceuticals、Bayer、Novartis、Roche、Biogen、Pfizer、Coherus BioSciences、Amgen、Bausch Health Companies、Viatris ・産業チェーン及び販売チャネル分析 - 抗血管内皮増殖因子治療薬の産業チェーン分析 - 抗血管内皮増殖因子治療薬の原材料 - 抗血管内皮増殖因子治療薬の生産プロセス - 抗血管内皮増殖因子治療薬の販売及びマーケティング - 抗血管内皮増殖因子治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 抗血管内皮増殖因子治療薬の産業動向 - 抗血管内皮増殖因子治療薬のマーケットドライバー - 抗血管内皮増殖因子治療薬の課題 - 抗血管内皮増殖因子治療薬の阻害要因 ・主な調査結果 |
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or medication, is the use of medications that block vascular endothelial growth factor.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Anti-Vascular Endothelial Growth Factor Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Anti-Vascular Endothelial Growth Factor Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Anti-Vascular Endothelial Growth Factor Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Anti-Vascular Endothelial Growth Factor Therapeutic include Regeneron Pharmaceuticals, Bayer, Novartis, Roche, Biogen, Pfizer, Coherus BioSciences, Amgen and Bausch Health Companies, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Anti-Vascular Endothelial Growth Factor Therapeutic manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Anti-Vascular Endothelial Growth Factor Therapeutic market. Further, it explains the major drivers and regional dynamics of the global Anti-Vascular Endothelial Growth Factor Therapeutic market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Regeneron Pharmaceuticals
Bayer
Novartis
Roche
Biogen
Pfizer
Coherus BioSciences
Amgen
Bausch Health Companies
Viatris
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Anti-Vascular Endothelial Growth Factor Therapeutic Segment by Type
Aflibercept (Eylea)
Ranibizumab (Lucentis)
Brolucizumab (Beovu)
Others
Anti-Vascular Endothelial Growth Factor Therapeutic Segment by Application
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Anti-Vascular Endothelial Growth Factor Therapeutic market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Anti-Vascular Endothelial Growth Factor Therapeutic, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Anti-Vascular Endothelial Growth Factor Therapeutic, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Anti-Vascular Endothelial Growth Factor Therapeutic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-Vascular Endothelial Growth Factor Therapeutic sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Anti-Vascular Endothelial Growth Factor Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Anti-Vascular Endothelial Growth Factor Therapeutic sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Regeneron Pharmaceuticals, Bayer, Novartis, Roche, Biogen, Pfizer, Coherus BioSciences, Amgen and Bausch Health Companies, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Anti-Vascular Endothelial Growth Factor Therapeutic in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Anti-Vascular Endothelial Growth Factor Therapeutic manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Vascular Endothelial Growth Factor Therapeutic sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Anti-Vascular Endothelial Growth Factor Therapeutic Product Introduction
1.2 Market by Type
1.2.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Aflibercept (Eylea)
1.2.3 Ranibizumab (Lucentis)
1.2.4 Brolucizumab (Beovu)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Macular Edema
1.3.3 Diabetic Retinopathy
1.3.4 Retinal Vein Occlusion
1.3.5 Age-related Macular Degeneration
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Estimates and Forecasts 2017-2028
2.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Estimates and Forecasts 2017-2028
2.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Region
2.4.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Region (2017-2022)
2.4.2 Global Sales Anti-Vascular Endothelial Growth Factor Therapeutic by Region (2023-2028)
2.5 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region
2.5.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region (2017-2022)
2.5.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Manufacturers
3.1.1 Global Top Anti-Vascular Endothelial Growth Factor Therapeutic Manufacturers by Sales (2017-2022)
3.1.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anti-Vascular Endothelial Growth Factor Therapeutic in 2021
3.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Manufacturers
3.2.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Manufacturers (2017-2022)
3.2.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Vascular Endothelial Growth Factor Therapeutic Revenue in 2021
3.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type
4.1.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Historical Sales by Type (2017-2022)
4.1.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Forecasted Sales by Type (2023-2028)
4.1.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Type (2017-2028)
4.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type
4.2.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Historical Revenue by Type (2017-2022)
4.2.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Forecasted Revenue by Type (2023-2028)
4.2.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Type (2017-2028)
4.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Price by Type
4.3.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Price by Type (2017-2022)
4.3.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application
5.1.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Historical Sales by Application (2017-2022)
5.1.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Forecasted Sales by Application (2023-2028)
5.1.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Application (2017-2028)
5.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application
5.2.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Historical Revenue by Application (2017-2022)
5.2.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Forecasted Revenue by Application (2023-2028)
5.2.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Application (2017-2028)
5.3 Global Anti-Vascular Endothelial Growth Factor Therapeutic Price by Application
5.3.1 Global Anti-Vascular Endothelial Growth Factor Therapeutic Price by Application (2017-2022)
5.3.2 Global Anti-Vascular Endothelial Growth Factor Therapeutic Price Forecast by Application (2023-2028)
6 North America
6.1 North America Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Type
6.1.1 North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2028)
6.1.2 North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2028)
6.2 North America Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Application
6.2.1 North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2028)
6.2.2 North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2028)
6.3 North America Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Country
6.3.1 North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2017-2028)
6.3.2 North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Type
7.1.1 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2028)
7.1.2 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2028)
7.2 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Application
7.2.1 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2028)
7.2.2 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2028)
7.3 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Country
7.3.1 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2017-2028)
7.3.2 Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Type
8.1.1 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2028)
8.1.2 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2028)
8.2 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Application
8.2.1 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2028)
8.2.2 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2028)
8.3 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Region
8.3.1 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Region (2017-2028)
8.3.2 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Type
9.1.1 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2028)
9.1.2 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2028)
9.2 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Application
9.2.1 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2028)
9.2.2 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2028)
9.3 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Country
9.3.1 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2017-2028)
9.3.2 Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Type
10.1.1 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2028)
10.1.2 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2028)
10.2 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Application
10.2.1 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2028)
10.2.2 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2028)
10.3 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Market Size by Country
10.3.1 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2017-2028)
10.3.2 Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Corporation Information
11.1.2 Regeneron Pharmaceuticals Overview
11.1.3 Regeneron Pharmaceuticals Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Regeneron Pharmaceuticals Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Regeneron Pharmaceuticals Recent Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Overview
11.2.3 Bayer Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bayer Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayer Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Overview
11.3.3 Novartis Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Novartis Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novartis Recent Developments
11.4 Roche
11.4.1 Roche Corporation Information
11.4.2 Roche Overview
11.4.3 Roche Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Roche Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Roche Recent Developments
11.5 Biogen
11.5.1 Biogen Corporation Information
11.5.2 Biogen Overview
11.5.3 Biogen Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Biogen Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Biogen Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pfizer Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Coherus BioSciences
11.7.1 Coherus BioSciences Corporation Information
11.7.2 Coherus BioSciences Overview
11.7.3 Coherus BioSciences Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Coherus BioSciences Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Coherus BioSciences Recent Developments
11.8 Amgen
11.8.1 Amgen Corporation Information
11.8.2 Amgen Overview
11.8.3 Amgen Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Amgen Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Amgen Recent Developments
11.9 Bausch Health Companies
11.9.1 Bausch Health Companies Corporation Information
11.9.2 Bausch Health Companies Overview
11.9.3 Bausch Health Companies Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Bausch Health Companies Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Bausch Health Companies Recent Developments
11.10 Viatris
11.10.1 Viatris Corporation Information
11.10.2 Viatris Overview
11.10.3 Viatris Anti-Vascular Endothelial Growth Factor Therapeutic Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Viatris Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Viatris Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anti-Vascular Endothelial Growth Factor Therapeutic Industry Chain Analysis
12.2 Anti-Vascular Endothelial Growth Factor Therapeutic Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Vascular Endothelial Growth Factor Therapeutic Production Mode & Process
12.4 Anti-Vascular Endothelial Growth Factor Therapeutic Sales and Marketing
12.4.1 Anti-Vascular Endothelial Growth Factor Therapeutic Sales Channels
12.4.2 Anti-Vascular Endothelial Growth Factor Therapeutic Distributors
12.5 Anti-Vascular Endothelial Growth Factor Therapeutic Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Anti-Vascular Endothelial Growth Factor Therapeutic Industry Trends
13.2 Anti-Vascular Endothelial Growth Factor Therapeutic Market Drivers
13.3 Anti-Vascular Endothelial Growth Factor Therapeutic Market Challenges
13.4 Anti-Vascular Endothelial Growth Factor Therapeutic Market Restraints
14 Key Findings in The Global Anti-Vascular Endothelial Growth Factor Therapeutic Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Aflibercept (Eylea)
Table 3. Major Manufacturers of Ranibizumab (Lucentis)
Table 4. Major Manufacturers of Brolucizumab (Beovu)
Table 5. Major Manufacturers of Others
Table 6. Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Region (2017-2022) & (K Units)
Table 9. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Region (2017-2022)
Table 10. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Region (2023-2028) & (K Units)
Table 11. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Region (2023-2028)
Table 12. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Region (2017-2022)
Table 14. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Region (2023-2028)
Table 16. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Manufacturers (2017-2022)
Table 18. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Manufacturers (2017-2022)
Table 20. Anti-Vascular Endothelial Growth Factor Therapeutic Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global Anti-Vascular Endothelial Growth Factor Therapeutic Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Anti-Vascular Endothelial Growth Factor Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Vascular Endothelial Growth Factor Therapeutic as of 2021)
Table 23. Anti-Vascular Endothelial Growth Factor Therapeutic Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Anti-Vascular Endothelial Growth Factor Therapeutic Product Offered
Table 25. Date of Manufacturers Enter into Anti-Vascular Endothelial Growth Factor Therapeutic Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2022) & (K Units)
Table 28. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2023-2028) & (K Units)
Table 29. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Type (2017-2022)
Table 30. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Type (2023-2028)
Table 31. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Type (2017-2022)
Table 34. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Type (2023-2028)
Table 35. Anti-Vascular Endothelial Growth Factor Therapeutic Price by Type (2017-2022) & (US$/Unit)
Table 36. Global Anti-Vascular Endothelial Growth Factor Therapeutic Price Forecast by Type (2023-2028) & (US$/Unit)
Table 37. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2022) & (K Units)
Table 38. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2023-2028) & (K Units)
Table 39. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Application (2017-2022)
Table 40. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Application (2023-2028)
Table 41. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Application (2017-2022)
Table 44. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Application (2023-2028)
Table 45. Anti-Vascular Endothelial Growth Factor Therapeutic Price by Application (2017-2022) & (US$/Unit)
Table 46. Global Anti-Vascular Endothelial Growth Factor Therapeutic Price Forecast by Application (2023-2028) & (US$/Unit)
Table 47. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2022) & (K Units)
Table 48. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2023-2028) & (K Units)
Table 49. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2022) & (K Units)
Table 52. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2023-2028) & (K Units)
Table 53. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2017-2022) & (K Units)
Table 56. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2023-2028) & (K Units)
Table 57. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2022) & (K Units)
Table 60. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2023-2028) & (K Units)
Table 61. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2022) & (K Units)
Table 64. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2023-2028) & (K Units)
Table 65. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2017-2022) & (K Units)
Table 68. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2023-2028) & (K Units)
Table 69. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2022) & (K Units)
Table 84. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2023-2028) & (K Units)
Table 85. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2022) & (K Units)
Table 88. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2023-2028) & (K Units)
Table 89. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue by Country (2023-2028) & (US$ Million)
Table 107. Regeneron Pharmaceuticals Corporation Information
Table 108. Regeneron Pharmaceuticals Description and Major Businesses
Table 109. Regeneron Pharmaceuticals Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. Regeneron Pharmaceuticals Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Regeneron Pharmaceuticals Recent Developments
Table 112. Bayer Corporation Information
Table 113. Bayer Description and Major Businesses
Table 114. Bayer Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. Bayer Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Bayer Recent Developments
Table 117. Novartis Corporation Information
Table 118. Novartis Description and Major Businesses
Table 119. Novartis Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. Novartis Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Novartis Recent Developments
Table 122. Roche Corporation Information
Table 123. Roche Description and Major Businesses
Table 124. Roche Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Roche Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Roche Recent Developments
Table 127. Biogen Corporation Information
Table 128. Biogen Description and Major Businesses
Table 129. Biogen Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. Biogen Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Biogen Recent Developments
Table 132. Pfizer Corporation Information
Table 133. Pfizer Description and Major Businesses
Table 134. Pfizer Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Pfizer Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Pfizer Recent Developments
Table 137. Coherus BioSciences Corporation Information
Table 138. Coherus BioSciences Description and Major Businesses
Table 139. Coherus BioSciences Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 140. Coherus BioSciences Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Coherus BioSciences Recent Developments
Table 142. Amgen Corporation Information
Table 143. Amgen Description and Major Businesses
Table 144. Amgen Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 145. Amgen Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Amgen Recent Developments
Table 147. Bausch Health Companies Corporation Information
Table 148. Bausch Health Companies Description and Major Businesses
Table 149. Bausch Health Companies Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 150. Bausch Health Companies Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Bausch Health Companies Recent Developments
Table 152. Viatris Corporation Information
Table 153. Viatris Description and Major Businesses
Table 154. Viatris Anti-Vascular Endothelial Growth Factor Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 155. Viatris Anti-Vascular Endothelial Growth Factor Therapeutic Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Viatris Recent Developments
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Anti-Vascular Endothelial Growth Factor Therapeutic Distributors List
Table 160. Anti-Vascular Endothelial Growth Factor Therapeutic Customers List
Table 161. Anti-Vascular Endothelial Growth Factor Therapeutic Market Trends
Table 162. Anti-Vascular Endothelial Growth Factor Therapeutic Market Drivers
Table 163. Anti-Vascular Endothelial Growth Factor Therapeutic Market Challenges
Table 164. Anti-Vascular Endothelial Growth Factor Therapeutic Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Vascular Endothelial Growth Factor Therapeutic Product Picture
Figure 2. Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Share by Type in 2021 & 2028
Figure 3. Aflibercept (Eylea) Product Picture
Figure 4. Ranibizumab (Lucentis) Product Picture
Figure 5. Brolucizumab (Beovu) Product Picture
Figure 6. Others Product Picture
Figure 7. Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Share by Application in 2021 & 2028
Figure 8. Macular Edema
Figure 9. Diabetic Retinopathy
Figure 10. Retinal Vein Occlusion
Figure 11. Age-related Macular Degeneration
Figure 12. Others
Figure 13. Anti-Vascular Endothelial Growth Factor Therapeutic Report Years Considered
Figure 14. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales 2017-2028 (K Units)
Figure 15. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue 2017-2028 (US$ Million)
Figure 17. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 18. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Region (2017-2022)
Figure 19. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Region (2023-2028)
Figure 20. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales YoY (2017-2028) & (K Units)
Figure 21. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales YoY (2017-2028) & (K Units)
Figure 23. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales YoY (2017-2028) & (K Units)
Figure 25. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales YoY (2017-2028) & (K Units)
Figure 27. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales YoY (2017-2028) & (K Units)
Figure 29. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue YoY (2017-2028) & (US$ Million)
Figure 30. The Anti-Vascular Endothelial Growth Factor Therapeutic Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 31. The Top 5 and 10 Largest Manufacturers of Anti-Vascular Endothelial Growth Factor Therapeutic in the World: Market Share by Anti-Vascular Endothelial Growth Factor Therapeutic Revenue in 2021
Figure 32. Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 33. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Type (2017-2028)
Figure 34. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Type (2017-2028)
Figure 35. Global Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Application (2017-2028)
Figure 36. Global Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Application (2017-2028)
Figure 37. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Type (2017-2028)
Figure 38. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Type (2017-2028)
Figure 39. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Application (2017-2028)
Figure 40. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Application (2017-2028)
Figure 41. North America Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Country (2017-2028)
Figure 42. North America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Country (2017-2028)
Figure 43. United States Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 44. Canada Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 45. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Type (2017-2028)
Figure 46. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Type (2017-2028)
Figure 47. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Application (2017-2028)
Figure 48. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Application (2017-2028)
Figure 49. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Country (2017-2028)
Figure 50. Europe Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Country (2017-2028)
Figure 51. Germany Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 52. France Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 53. U.K. Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 54. Italy Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 55. Russia Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 56. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Type (2017-2028)
Figure 57. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Type (2017-2028)
Figure 58. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Application (2017-2028)
Figure 59. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Application (2017-2028)
Figure 60. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Region (2017-2028)
Figure 61. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Region (2017-2028)
Figure 62. China Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 63. Japan Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 64. South Korea Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 65. India Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 66. Australia Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 67. China Taiwan Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 68. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 69. Thailand Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 70. Malaysia Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 71. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Type (2017-2028)
Figure 72. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Type (2017-2028)
Figure 73. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Application (2017-2028)
Figure 74. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Application (2017-2028)
Figure 75. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Country (2017-2028)
Figure 76. Latin America Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Country (2017-2028)
Figure 77. Mexico Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 78. Brazil Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 79. Argentina Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 80. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Sales Share by Country (2017-2028)
Figure 85. Middle East and Africa Anti-Vascular Endothelial Growth Factor Therapeutic Revenue Share by Country (2017-2028)
Figure 86. Turkey Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 87. Saudi Arabia Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 88. UAE Anti-Vascular Endothelial Growth Factor Therapeutic Revenue (2017-2028) & (US$ Million)
Figure 89. Anti-Vascular Endothelial Growth Factor Therapeutic Value Chain
Figure 90. Anti-Vascular Endothelial Growth Factor Therapeutic Production Process
Figure 91. Channels of Distribution
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed